Kei Shibuya1, Tatsuya Ohno2, Hiroyuki Katoh2, Masahiko Okamoto2, Shintaro Shiba3, Yoshinori Koyama4, Satoru Kakizaki5, Ken Shirabe6, Takashi Nakano7. 1. Gunma University Heavy Ion Medical Center, Maebashi, Japan; Department of Radiation Oncology, Gunma University Hospital, Maebashi, Japan. Electronic address: shibukei@gunma-u.ac.jp. 2. Gunma University Heavy Ion Medical Center, Maebashi, Japan. 3. Department of Radiation Oncology, Gunma University Hospital, Maebashi, Japan. 4. Department of Radiology, National Hospital Organization Shibukawa Medical Center, Japan. 5. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan. 6. Department of Hepatobiliary and Pancreatic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan. 7. Gunma University Heavy Ion Medical Center, Maebashi, Japan; Department of Radiation Oncology, Gunma University Hospital, Maebashi, Japan.
Abstract
BACKGROUND AND PURPOSE: To evaluate the safety of carbon-ion radiotherapy (C-ion RT) using 60 Gy (relative biological effectiveness, RBE) in four fractions for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The primary outcome was acute toxicities within 90 days. The secondary outcomes were late toxicities, local control, and progression-free survival and overall survival rates. The key inclusion criteria were as follows: (1) 3 cm or larger HCC without major vascular invasion and not adjacent to the alimentary tract; (2) Child-Pugh's grade A/B; and (3) without extrahepatic metastasis. RESULTS: A total of 21 cases were analyzed between October 2012 and April 2016. The median follow-up period among the 17 survivors was 24.2 (range: 6.3-43.7) months. Grade 3 or higher acute toxicity was not observed, while three (14.3%) of the 21 patients experienced grade 3 late toxicities. The 1- and 2-year local control, progression-free survival, and overall survival rates were 100% and 92.3%, 81.0% and 50.0%, and 90.5% and 80.0%, respectively. CONCLUSION: C-ion RT using 60 Gy (RBE) in four fractions was safe and achieved promising local tumor control.
BACKGROUND AND PURPOSE: To evaluate the safety of carbon-ion radiotherapy (C-ion RT) using 60 Gy (relative biological effectiveness, RBE) in four fractions for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The primary outcome was acute toxicities within 90 days. The secondary outcomes were late toxicities, local control, and progression-free survival and overall survival rates. The key inclusion criteria were as follows: (1) 3 cm or larger HCC without major vascular invasion and not adjacent to the alimentary tract; (2) Child-Pugh's grade A/B; and (3) without extrahepatic metastasis. RESULTS: A total of 21 cases were analyzed between October 2012 and April 2016. The median follow-up period among the 17 survivors was 24.2 (range: 6.3-43.7) months. Grade 3 or higher acute toxicity was not observed, while three (14.3%) of the 21 patients experienced grade 3 late toxicities. The 1- and 2-year local control, progression-free survival, and overall survival rates were 100% and 92.3%, 81.0% and 50.0%, and 90.5% and 80.0%, respectively. CONCLUSION: C-ion RT using 60 Gy (RBE) in four fractions was safe and achieved promising local tumor control.
Authors: Timothy D Malouff; Anita Mahajan; Sunil Krishnan; Chris Beltran; Danushka S Seneviratne; Daniel Michael Trifiletti Journal: Front Oncol Date: 2020-02-04 Impact factor: 5.738